Prescription digital therapeutics are software-based treatments, usually smartphone apps, that a clinician prescribes and that clear the FDA's medical device pathway. A handful have been authorized in psychiatry. The evidence is real but limited, and reimbursement is the biggest barrier to their use.
Key takeaways
- Prescription digital therapeutics are software treatments that clear the FDA's medical device pathway and are prescribed by a clinician, unlike ordinary wellness apps.
- FDA clearance or authorization is not the same as drug approval; it clears a meaningful but limited bar, and the authorized use is often narrower than the marketing.
- The evidence is real but limited, with small, often company-run trials and much lower engagement in real-world use than in studies.
- Reimbursement is the biggest barrier: these products fit neither drug nor service billing, and without coverage, prescribing collapses.
What a prescription digital therapeutic actually is
A prescription digital therapeutic is software, usually a smartphone app, that's meant to treat a medical condition and that a clinician prescribes the way they'd prescribe a medication. The distinction that matters is regulatory. To be a prescription product rather than a wellness app, the software goes through the Food and Drug Administration as a medical device. That's a different category from the tens of thousands of meditation and mood-tracking apps in the app stores, which make no medical claims and get no FDA review. The FDA runs a Digital Health Center of Excellence that oversees this space.
Most of these products deliver a structured, evidence-based intervention, often a version of cognitive behavioral therapy, in software form. The pitch is that a proven therapy can be delivered consistently, on demand, and at scale, without needing a therapist for every session. That's a reasonable idea. The question is always whether a specific product actually does what it claims, and whether the authorization behind it means what the marketing implies.
What's authorized versus what's marketed
This is where care matters. The FDA has authorized a small number of digital therapeutics through its device pathways, most often the 510(k) clearance or the De Novo route for lower-risk novel devices. It's important to be precise about what that means. FDA clearance or authorization is not the same as FDA approval of a drug, and it doesn't certify that a product is highly effective. It means the agency reviewed the device and allowed it to be marketed for a specific use, often based on it being substantially equivalent to an existing device or on evidence of reasonable safety and effectiveness for a narrow indication.
The marketing frequently blurs this. A product authorized for one specific condition can be promoted in language that sounds broader than the actual indication. Some companies describe an app as "FDA cleared" in ways that lead patients and even clinicians to overestimate the strength of the evidence. The honest reading is that authorization is a real regulatory milestone that clears a meaningful bar, but it's a floor, not a guarantee of strong outcomes, and the specific authorized use is often narrower than the pitch.
The evidence and its limits
For the products that have been authorized, there's usually real clinical data behind them, often randomized trials showing a benefit over a control condition for a defined population. That's genuine, and it's more than most health apps can claim. But the limits are worth stating plainly. Trials of digital therapeutics are frequently small, short, and run by or with the company that makes the product. Control conditions vary in quality. Real-world engagement tends to be much lower than in a trial, and a therapy the patient stops opening after two weeks doesn't help anyone. Durability past the study window is often unknown.
So the fair summary is cautious optimism. The category is legitimate, some products have decent evidence for specific uses, and software delivery solves real access problems. It is not a settled question that these tools work as well in ordinary practice as they do in a trial, and the field is young enough that claims should be read against the actual indication and the actual data, not the brochure.
Why reimbursement keeps stalling
The single biggest obstacle isn't the science. It's payment. A prescription digital therapeutic sits awkwardly between categories. It isn't a drug, so it doesn't move through pharmacy benefits the way a medication does. It isn't a service a clinician performs, so it doesn't fit neatly into the usual billing codes. That leaves it in a gap where payers often have no established way to cover it, and without coverage, prescribing collapses because patients won't pay out of pocket for an app.
This gap has already been fatal for at least one prominent company in the space, which built authorized products and strong-looking evidence and still couldn't build a sustainable business because the reimbursement pathways weren't there. Efforts are underway to create dedicated payment pathways, including in Medicare and Medicaid, but progress has been slow. Until a clinician can prescribe one of these tools and expect it to be covered as routinely as a prescription, the category will keep punching below its potential, no matter how good the underlying software gets.
Common questions
What is a prescription digital therapeutic?
It's software, usually a smartphone app, meant to treat a medical condition, that a clinician prescribes and that has gone through the FDA's medical device pathway. That regulatory step is what separates it from the many wellness apps that make no medical claims and get no FDA review.
Does FDA clearance mean an app is proven to work well?
No. FDA clearance or authorization is not the same as drug approval. It means the agency reviewed the device and allowed it to be marketed for a specific use, often based on substantial equivalence or reasonable safety and effectiveness for a narrow indication. It's a floor, not a guarantee of strong outcomes.
Why can't my psychiatrist just prescribe one?
Usually because of payment. These products fit neither pharmacy benefits nor standard clinical billing codes, so payers often have no established way to cover them. Without coverage, few patients will pay out of pocket, and prescribing rarely takes hold.
Sources
- FDA Digital Health Center of Excellence. https://www.fda.gov/medical-devices/digital-health-center-excellence
- FDA. How to determine if your product is a medical device, and device authorization pathways (510(k), De Novo). https://www.fda.gov/medical-devices/digital-health-center-excellence/software-medical-device-samd
- FDA. Premarket notification 510(k) overview. https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k